CTOs on the Move

GTC Biotherapeutics, Inc.

www.gtc-bio.com

 
GTC Biotherapeutics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.gtc-bio.com
  • 175 Crossing Blvd Ste 410
    Framingham, MA USA '01702
  • Phone: 508.620.9700

Executives

Name Title Contact Details

Similar Companies

CapsCanada

Were one of the world’s leading providers of high quality, empty, hard capsules serving global pharmaceutical and dietary supplement markets.

Verifique

Verifique is a company that provides fast and easy at-home test kits to detect unwanted substances in food, candies, powders, vape pens, edibles, pills, and powders. Their mission is to keep families and communities safe by creating easy-to-use narcoti...

ApexCare

ApexCare is a Salem, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eli Lilly

Lilly makes medicines that help people live longer, healthier, more active lives. We were founded by Eli Lilly in 1876, and are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity, and respect for people. We make medicines that help people live longer, healthier, more active lives.

Phathom Pharmaceuticals

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.